Skrede M - Search Results

1

Association studies of estrogen receptor polymorphisms in a Norwegian testicular cancer population.

Heimdal K, Andersen TI, Skrede M, Fosså SD, Berg K, Børresen AL. Heimdal K, et al. Among authors: skrede m. Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):123-6. Cancer Epidemiol Biomarkers Prev. 1995. PMID: 7742719

2

TP53 allele loss, mutations and expression in malignant melanoma.

Flørenes VA, Oyjord T, Holm R, Skrede M, Børresen AL, Nesland JM, Fodstad O. Flørenes VA, et al. Among authors: skrede m. Br J Cancer. 1994 Feb;69(2):253-9. doi: 10.1038/bjc.1994.48. Br J Cancer. 1994. PMID: 7905277 Free PMC article.

3

Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility.

Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K, Børresen AL. Andersen TI, et al. Among authors: skrede m. Hum Genet. 1994 Dec;94(6):665-70. doi: 10.1007/BF00206961. Hum Genet. 1994. PMID: 7989041

4

Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis.

Ottestad L, Andersen TI, Nesland JM, Skrede M, Tveit KM, Nustad K, Børresen AL. Ottestad L, et al. Among authors: skrede m. Acta Oncol. 1993;32(3):289-94. doi: 10.3109/02841869309093597. Acta Oncol. 1993. PMID: 8100712

5

Screening for ESR mutations in breast and ovarian cancer patients.

Anderson TI, Wooster R, Laake K, Collins N, Warren W, Skrede M, Elles R, Tveit KM, Johnston SR, Dowsett M, Olsen AO, Møller P, Stratton MR, Børresen-Dale AL. Anderson TI, et al. Among authors: skrede m. Hum Mutat. 1997;9(6):531-6. doi: 10.1002/(SICI)1098-1004(1997)9:6<531::AID-HUMU6>3.0.CO;2-4. Hum Mutat. 1997. PMID: 9195227

6

Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening.

Andersen TI, Eiken HG, Couch F, Kaada G, Skrede M, Johnsen H, Aloysius TA, Tveit KM, Tranebjaerg L, Dørum A, Møller P, Weber BL, Børresen-Dale AL. Andersen TI, et al. Among authors: skrede m. Hum Mutat. 1998;11(2):166-74. doi: 10.1002/(SICI)1098-1004(1998)11:2<166::AID-HUMU10>3.0.CO;2-X. Hum Mutat. 1998. PMID: 9482581

7

Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme.

Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Flørenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad O. Maelandsmo GM, et al. Among authors: skrede m. Cancer Res. 1996 Dec 1;56(23):5490-8. Cancer Res. 1996. PMID: 8968106

8

Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma.

Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B, Tropé CG, Flørenes VA. Davidson B, et al. Among authors: skrede m. Clin Cancer Res. 2003 Jun;9(6):2248-59. Clin Cancer Res. 2003. PMID: 12796393

9

The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma.

Sandhu V, Wedge DC, Bowitz Lothe IM, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, Lingjærde OC, Børresen-Dale AL, Ikdahl T, Van Loo P, Nord S, Kure EH. Sandhu V, et al. Among authors: skrede ml. Cancer Res. 2016 Sep 1;76(17):5092-102. doi: 10.1158/0008-5472.CAN-16-0658. Epub 2016 Aug 3. Cancer Res. 2016. PMID: 27488532

10

Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index.

Hetland TE, Kærn J, Skrede M, Sandstad B, Tropé C, Davidson B, Flørenes VA. Hetland TE, et al. Among authors: skrede m. Cancer Chemother Pharmacol. 2012 May;69(5):1307-14. doi: 10.1007/s00280-012-1835-9. Cancer Chemother Pharmacol. 2012. PMID: 22302409

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

31 results

Search Page